OCUMENSION-B(01477): 2024 annual income is expected to increase by 65.6%-70.5% compared to the previous year.

OCUMENSION-B (01477) announces that for the year ending December 31, 2024, the revenue is expected to be approximately RMB 4.08 billion to 4.20 billion, representing a year-on-year growth of 65.6%-70.5%. The significant increase in revenue for 2024 is mainly attributed to the company's acquisition of Alcon transfer products and the introduction of licensed products, which has significantly increased the company's revenue scale. The revenue generated from the sales of other ophthalmic pharmaceutical products has also increased substantially. During the reporting period, the impact of transfer products and licensed products on the company includes enriching the product line, bringing considerable economic benefits to the company, especially the products related to dry eye syndrome such as Siren. It further enhances the company's competitive position in the field of ophthalmic drugs, especially strengthening the company's business competitiveness in the field of dry eye syndrome. With the accumulation of a wealth of experience and market share, the company is capable of providing more comprehensive and advanced treatment options, further meeting patient needs and expanding the company's market share. By optimizing resource allocation and market promotion strategies, combined with the company's strong commercialization and localization capabilities, transfer products and licensed products have become a stable source of long-term income for the company. In addition, during the reporting period, the company's core product, UVVYO (fluocinolone acetonide intravitreal implant), showed rapid growth after being included in the new version of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List". Meanwhile, the commercial team actively expanded hospital coverage, deeply explored the commercial potential of products such as AUQIN and SILIDAR to drive the stable growth of over a dozen commercialized products, thereby gaining a larger market share.